RELA and inflammatory bowel disease: According to previous findings and analyzed results in our research, the key molecular mechanisms of CR against UC are summarized as anti-inflammatory, immunoregulatory, anti-oxidant and anti-fibrosis by target to core genes and pathways, including TP53, HSP90AA1, STAT3, ESR1, MYC, RELA, the PI3K/Akt signaling pathway, Th17 cell differentiation and inflammatory bowel disease signal pathway.